This points to a more careful view about the potential benefits of PPARβ/δ agonists in the treatment of cardiovascular diseases, as the proper balance between cardiomyocytic and vascular PPARβ/δ seems to be crucial for cardiac health, especially under ischemic conditions. Here, PPARD is linked to cardiovascular disorder.